C12Y 304/21021
Coagulation factor viia
Official title: Coagulation factor VIIa (3.4.21.21)
C12Y304/21021 (Coagulation factor viia) appears on 255 US grants and 478 published applications in this corpus.
Search patents in C12Y- Granted patents
- 255
- Published applications
- 478
- Assignees
- 134
- Inventors
- 505
- Latest grant
- 18 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1983 | 1 | 0 |
| 1984 | 2 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 1 | 0 |
| 1988 | 1 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 2 | 0 |
| 1994 | 2 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 2 | 0 |
| 1998 | 4 | 0 |
| 1999 | 5 | 0 |
| 2000 | 2 | 0 |
| 2001 | 2 | 3 |
| 2002 | 3 | 4 |
| 2003 | 1 | 18 |
| 2004 | 5 | 15 |
| 2005 | 4 | 13 |
| 2006 | 4 | 34 |
| 2007 | 6 | 16 |
| 2008 | 14 | 29 |
| 2009 | 6 | 25 |
| 2010 | 20 | 18 |
| 2011 | 8 | 23 |
| 2012 | 9 | 21 |
| 2013 | 5 | 16 |
| 2014 | 17 | 18 |
| 2015 | 15 | 31 |
| 2016 | 17 | 42 |
| 2017 | 16 | 33 |
| 2018 | 13 | 22 |
| 2019 | 15 | 26 |
| 2020 | 17 | 16 |
| 2021 | 13 | 18 |
| 2022 | 6 | 15 |
| 2023 | 8 | 9 |
| 2024 | 2 | 5 |
| 2025 | 3 | 4 |
| 2026 | 4 | 4 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Inter-application workflow performance analytics18 Aug 2026US 12,711,443 B2Box, Inc.
- Gla domains as therapeutic agents14 Jul 2026US 12,678,481 B2Gladiator Biosciences, Inc.
- Tissue factor-targeting CAR-NK and CAR-T cell therapy19 May 2026US 12,630,605 B2Ohio State Innovation Foundation
- Gla domains as targeting agents20 Jan 2026US 12,527,836 B2Gladiator Biosciences, Inc.
- Methods of producing long acting CTP-modified growth hormone polypeptides4 Nov 2025US 12,459,982 B2Opko Biologistics Ltd.
- Human factor vii deletion constructs for treating cancer8 Oct 2026US 2026/0306592 A1The Cleveland Clinic Foundation
- Oligonucleotide Modulators Activating Factor VII Expression and Use Thereof in Treatment of Hemophilia10 Sep 2026US 2026/0265739 A1
- Combination therapies with an anti-factor xi/factor xia antibody13 Aug 2026US 2026/0232796 A1Anthos Therapeutics, Inc.
- Treatment of hemophilia a with fitusiran2 Jul 2026US 2026/0185097 A1Genzyme Corporation
- Lipid nanoparticles comprising mannose or uses thereof28 Aug 2025US 2025/0269053 A1Enhancedbio Inc.
Most cited
By later US patents
- Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor288US 7,282,199 B2The Trustees of the University of Pennsylvania · 2007
- Site specific delivery of nucleic acids by combining targeting ligands with endosomolytic components256US 9,345,780 B2Tekmira Pharmaceuticals Corporation · 2016
- Adeno-associated virus (AAV) serotype 8 sequences, vectors containing the same, and uses therefor220US 7,790,449 B2The Trustees of the University of Pennsylvania · 2010
- Immunoglobulin chimeric monomer-dimer hybrids215US 7,404,956 B2Syntonix Pharmaceuticals, Inc. · 2008
- Expression of factor VII activity in mammalian cells201US 4,784,950 AZymoGenetics, Inc. · 1988